Biotechnology Subcommittee Says Legal Safeguards Are Needed
Ministry Backs Amendment to Industrial Technology Protection Act
Domestic Toxin Market Exports Expected to Gain Momentum

Momentum is building behind discussions on removing botulinum toxin, used to reduce wrinkles, from the list of national core technologies. The move is seen as a preliminary step toward lifting the regulation, as concerns have mounted that it is hampering domestic companies' exports and undermining their competitiveness.


Botox-related image. The Asia Business Daily DB.

Botox-related image. The Asia Business Daily DB.

View original image

According to industry sources on October 20, the biotechnology subcommittee under the Industrial Technology Protection Committee recently said that legal safeguards are needed to ensure penalties remain in place for past technology leaks as it reviews whether to remove botulinum toxin from the list of national core technologies. The concern is that if the designation is lifted, the legal basis for punishing leaks that occurred while the technology was designated could be weakened.


The Ministry of Trade, Industry and Energy is also said to have conveyed its verbal support for an amendment to the Act on Prevention of Divulgence and Protection of Industrial Technology, sponsored by Park Heeseung of the Democratic Party of Korea, and is monitoring its progress. The bill would allow authorities to hold parties accountable for illegal leaks that occurred while a technology was designated as a national core technology, even if that designation is later lifted. The move is seen as a plan to first close the potential gap in penalties through a revision of the law, and then proceed with lifting the designation.


The botulinum toxin production process was designated a national core technology in 2010, and the strain was designated in 2016. As a result, domestic companies have had to obtain government approval each time they export toxin-related technology overseas, establish local production facilities or joint ventures, or attract investment. Industry sources estimate that related procedures take an average of 4 to 6 months to receive approval, and sometimes more than a year, resulting in annual losses of 90 billion to 100 billion won due to canceled overseas contracts and delays in entering markets.

K-Toxin Exports Near $500 Million: Will the Shackles Be Removed? Delisting as a National Core Technology Picks Up Pace View original image

Industry insiders say there is little practical benefit to protecting the technology, given that toxin cultivation and purification techniques have already been commercialized overseas. They argue that there is no significant technological gap between countries in the botulinum toxin manufacturing process, a technology known since the 1960s, that would justify its designation as a national core technology. Choi Gyujin, an attorney at DaeRyook & Aju who specializes in regulatory affairs in the bio and healthcare sectors, said, "More than 2,000 botulinum strains are registered in GenBank," adding, "The competitiveness of toxins depends more on Good Manufacturing Practice (GMP), regulatory approval capabilities, and branding than on the strains or manufacturing technology."


If the designation is lifted, the domestic toxin market is expected to gain momentum. South Korea's toxin exports surged 88% in three years, from $223.21 million in 2022 to $420.20 million last year. Exports also rose 47% year over year to $275.26 million in the first half of this year. There is growing expectation that overseas expansion will accelerate as companies broaden their approach beyond exporting finished products to include establishing local joint-venture plants and licensing out technology.



An industry source said, "I understand that there is now a consensus within the authorities that they recognize the difficulties companies are facing and that the system needs to change." The source added, "Once the parliamentary audit concludes and the amendment is actively discussed and passed by the National Assembly, the process of removing botulinum toxin from the list of national core technologies will also proceed in stages."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing